Financial Performance - The company reported a revenue of 1.2 billion RMB for the fiscal year 2023, representing a year-over-year growth of 15%[21]. - The company's operating revenue for 2024 is reported at ¥2,013,856,558, a decrease of 5.02% compared to ¥2,120,251,604 in 2023[26]. - Net profit attributable to shareholders for 2024 is ¥142,397,376, reflecting a significant decline of 68.67% from ¥454,437,474 in 2023[26]. - The net profit after deducting non-recurring gains and losses is ¥110,319,389.71 for 2024, down 75.07% from ¥442,470,555 in 2023[26]. - The company’s total revenue for 2024 was approximately ¥2.01 billion, a decrease of 5.02% compared to ¥2.12 billion in 2023[99]. - The revenue from ultrasound products was ¥1.18 billion, accounting for 58.75% of total revenue, with a year-on-year decline of 3.26%[99]. - The company achieved a gross margin of 63.78% in the medical device sector, down 3.93% from the previous year[100]. - International sales contributed ¥970.16 million, representing 48.17% of total revenue, with a growth of 3.27% year-on-year[99]. Research and Development - R&D and sales expenses increased year-on-year, with R&D expenses accounting for approximately 20% of current operating revenue, indicating a high level of strategic investment in new product lines[5]. - Research and development expenses increased by 10% to 120 million RMB, focusing on innovative medical technologies[21]. - The company has invested in R&D with expenditures of 328.96 million, 384.26 million, and 472.93 million yuan for the years 2022, 2023, and 2024, respectively, representing 18.66%, 18.12%, and 23.48% of total revenue[68]. - The company holds a total of 1,035 patents, including invention and utility model patents, and has been recognized as a "National High-tech Enterprise" since 2009, reflecting its strong R&D capabilities[68]. - The number of R&D personnel increased by 16.48% to 841, with a higher proportion of master's degree holders at 50.4%[109]. - The company is focusing on innovative medical devices, with several products classified as innovative medical devices under review[116]. Product Development and Launches - The company plans to rely on high-end and diversified product development strategies to continuously launch more competitive products and expand market share[4]. - New product launches include an advanced ultrasound diagnostic device expected to enhance imaging quality by 30%[21]. - The company launched high-end ultrasound machines S80 and P80 in 2024, marking a breakthrough in the high-end ultrasound field[54]. - The company has launched multiple new self-developed endoscopes, including various types of digestive and respiratory endoscopes, enhancing the user experience and aiming to elevate domestic endoscopy capabilities to handle more complex clinical scenarios[58]. - The company has introduced several new disposable medical devices intended for use with flexible endoscopes, including Disposable Needle Electrode, Disposable Coagulation Electrode, and Disposable Hot Biopsy Forceps, all classified as IIb devices[128]. Market Expansion - The company is expanding its market presence in Europe, targeting a 20% market share by the end of 2025[21]. - The company is actively expanding its minimally invasive surgical business and has introduced a team with extensive experience in surgical products and marketing[50]. - The company is expanding its market presence in Southeast Asia, targeting a 20% increase in sales in that region over the next fiscal year[196]. - The company has established a global marketing network covering nearly 170 countries and regions[82]. Strategic Initiatives - The company has initiated a strategic acquisition of a local competitor, which is projected to increase market penetration by 15%[21]. - The company has implemented several accounting policy changes effective January 1, 2024, including the adoption of new standards regarding the classification of current and non-current liabilities[27]. - The company has established a market value management plan approved on April 10, 2025, to enhance valuation[171]. - The "Quality and Return Dual Improvement" action plan has been implemented, focusing on share repurchase and high-end product launches[172]. Corporate Governance - The company has ensured compliance with corporate governance regulations, with a board of directors consisting of 7 members, including 3 independent directors[178]. - The company has established a performance evaluation and incentive mechanism for directors, supervisors, and senior management[181]. - The company operates independently from its controlling shareholder, ensuring no interference in decision-making[177]. Social Responsibility - The company’s efforts in social responsibility included providing free liver ultrasound examinations for patients with echinococcosis in western regions, contributing to the establishment of a comprehensive prevention and treatment system[95]. Financial Management - The cash inflow from investment activities in 2024 was CNY 1,015.99 million, an increase of 71.53% year-over-year, mainly due to increased redemptions of financial products[133]. - The cash outflow from investment activities surged to CNY 1,607.13 million, a significant increase of 295.70% compared to the previous year, primarily due to increased purchases of financial products[133]. - The total cash and cash equivalents decreased by CNY 202.67 million in 2024, a decline of 150.28% compared to the previous year, attributed to higher expenditures on financial products[134].

Core Viewpoint - AI is significantly transforming the productivity of the healthcare industry, with a focus on enhancing diagnostic efficiency and accuracy in medical institutions [1][2]. Group 1: AI in Healthcare - The Chinese government is promoting the "Artificial Intelligence +" initiative to better integrate digital technology with manufacturing and market advantages [2]. - At the recent China International Medical Equipment Fair (CMEF), AI was a prominent topic, with nearly 5,000 companies showcasing advanced AI medical products and services [2]. - The Vice President of KAILI Medical emphasized the importance of AI in primary healthcare, aiming to shift the market focus from hospitals to home healthcare [2]. Group 2: Market Position and Growth - KAILI Medical is a leading domestic medical device company, ranking fourth in the domestic ultrasound imaging diagnostic equipment market and first among domestic brands in digestive endoscopy [4]. - The medical device industry has experienced fluctuations due to centralized procurement and reduced hospital bidding demands, but the market is recovering due to large-scale equipment updates [4][5]. - The government has initiated policies to support equipment updates, with funding distributed based on a 9:1 principle between central and local governments [4]. Group 3: Impact of Centralized Procurement - Centralized procurement has led to a decrease in equipment sales prices; however, the increase in supply volume has positively impacted overall sales and market share for KAILI Medical [5]. - The company believes that success in centralized procurement relies on comprehensive strength and product competitiveness rather than just low prices [5]. Group 4: AI Product Development - KAILI Medical has been investing in AI technology since 2016, launching the world's first AI technology for automatic image capture in 2018, enhancing product performance [6]. - The company’s AI applications in the fields of obstetrics and gastroenterology have received positive feedback, with AI diagnostic accuracy exceeding 95% in radiology [6]. - The company is focusing on expanding AI clinical applications to assist doctors in various diagnostic scenarios [6]. Group 5: International Market Strategy - The impact of the recent "reciprocal tariffs" imposed by the U.S. is minimal for KAILI Medical, as U.S. market revenue constitutes less than 2% of total revenue [7]. - The company has established a solid overseas presence and plans to increase investments in international markets, particularly in Europe, Russia, India, and Latin America [8].

智通财经4月9日电，记者从开立医疗方面获悉，美国加征"对等关税"对公司影响不大，因为美国市场收 入在公司营业收入中的占比不到2%，且美国代理商已提前进行了适当备货。公司在海外布局多年、运 营较完善，近年来加强本地化建设，逐步在海外建立分公司。未来，公司会进一步加大海外市场投入， 重点在欧洲、俄罗斯、印度、拉美等地区拓展布局。（智通财经记者 何凡） 开立医疗回应美关税调整：公司美国市场收入占比不到2% ...

展会期间，超高端全身及妇产超声河图®S80、梦溪P80及高端智能便携超声天枢X11、天璇E11亮相， 产品搭载全新C-Field+天工智能平台，基于独有的场成像发射、自适应聚合重建技术，可获取更精准的 图像，同时基于XPUs混合硬件架构，为临床提供多科室智能解决方案。 在内镜诊疗领域，开立医疗新一代智慧内镜平台iEndo迎来首秀。该平台创新搭载独立GPU和超分辨成 像技术，搭配丰富镜种，塑造内外融合诊疗一体化智慧生态。 值得一提的是，在心血管介入领域，以临床需求为导向，开立医疗V-reader®血管内超声诊断系统和 SonoSound®导管组成的智能超宽频腔内影像方案，集造影和IVUS多模态影像联动、高帧频高速成像、 灵活操控部署模式、远程协同于一体，为医生提供更高效、易用的使用体验，推动了精准介入疗法的发 展和技术下沉。 本报讯 （记者王镜茹） 4月8日，第91届中国国际医疗器械博览会（CMEF）在国家会展中心（上海）开幕。深圳开立生物医疗 科技股份有限公司（以下简称"开立医疗"）携其AI专科解决方案及多款核心设备亮相，全方位彰显在智 慧医疗领域的前瞻性布局与深厚的自主创新实力。 依托自主研发的高端智能影像 ...

Core Viewpoint - The 91st China International Medical Equipment Fair (CMEF) showcased cutting-edge medical technologies and devices from nearly 5,000 global enterprises, emphasizing the theme of "Innovative Technology, Leading the Future" [1] Company Highlights - KaiLi Medical, a leading domestic enterprise in ultrasound medical imaging and endoscopy, presented its innovative products and solutions under the theme "Intelligent Wave, Surge Towards New" at CMEF, highlighting its comprehensive smart diagnosis and treatment ecosystem [3] - The company introduced several high-end products across four major product lines: ultrasound medical imaging, endoscopic diagnosis and treatment, minimally invasive surgery, and cardiovascular intervention, demonstrating its strong self-research capabilities [4] - In the ultrasound medical imaging sector, KaiLi Medical showcased its ultra-high-end full-body ultrasound product, HeTu® S80, and the intelligent obstetric ultrasound product, MengXi TMP80, both featuring advanced imaging technologies for enhanced clinical solutions [4] - The new generation of the iEndo smart endoscope platform was launched, utilizing a multi-core heterogeneous hardware architecture and advanced imaging technologies to improve early cancer screening and complex lesion diagnosis [6] - In minimally invasive surgery, the company presented the "LingZhu" 4K 3D fluorescence imaging platform, which integrates various imaging modalities for precise diagnosis and treatment [7] - The cardiovascular intervention segment featured the V-reader® series intravascular ultrasound diagnostic system, designed for flexible use in sterile environments, enhancing access to quality medical resources [8] R&D and Innovation - KaiLi Medical has significantly increased its R&D investment, with expenditures reaching 338 million yuan, a year-on-year increase of 28.33%, surpassing the total R&D expenses of 2022 [10] - The company has been at the forefront of AI applications in the medical field, having launched the world's first AI technology for automatic image capture in 2018, and recently achieved a significant milestone with the first domestic AI medical device for prenatal ultrasound [10] - The introduction of the 5G + AI cloud imaging platform at CMEF allows regional hospitals to utilize AI services across various ultrasound devices, addressing interoperability issues within medical networks [11] Strategic Vision - KaiLi Medical adheres to the philosophy of "Creating More Possibilities for Life," focusing on a multi-product line strategy and continuous investment in high-end product development, aiming to fill gaps in the domestic market and enhance its competitive advantage [15]

报名：首届全球眼科大会 | 议程更新 那么，本次 医学影像展区 都将展出哪些创新产品呢？一起来看看吧！ # GE医疗 展位 ：3R13 展品 ： "英雄"磁共振结合"Sonic深度学习平台" GE医疗 是一家全球领先的医疗科技、诊断药物和数字化解决方案的创新企业，致力于通过整合解决方案和服 务提升医疗效率和精准度。公司业务遍及 160多个国家和地区 ，年营收超196亿美元，拥有全球员工51,000 名。 GE医疗的 SIGNA Hero磁共振设备通过搭载人工智能深度学习Sonic平台 ，实现了"脑心同治"理念的落地。该 设备将传统超过一小时的检查时间缩短至半小时，仅需一次造影剂注射即可完成脑心联合评估，大幅提升检查 效率和成功率。此外，SIGNA Hero还具备 高分辨斑块成像功能 ，能够评估缺血性脑卒中和心脏病风险，为不 明原因卒中患者提供全面诊断信息。 基于SIGNA Hero的脑心同治及肿瘤精准诊疗应用方案已入选《2024年高端医疗装备推广应用项目》，并由天 津医科大学总医院牵头，联合多家医院进行临床应用研究。 # 飞利浦医疗 报名：首届全球骨科大会 | 议程更新 报名：首届全球心血管大会 | 奖项申报 ...

报名：首届全球眼科大会 | 议程更新 报名：首届全球心血管大会 | 奖项申报 报名：首届全球骨科大会 | 奖项评选 合作伙伴征集：2025全球手术机器人大会 2025年4月8日至11日， 第91届中国国际医疗器械（春季）博览会（CMEF） 将在上海国家会展中心拉开帷幕。作为亚太地区规模最大的医疗科技展会，CMEF始终 是行业风向标，不仅汇聚全球创新技术，更见证着产业发展的新趋势。本届展会预计吸引 全球30多个国家和地区的近 5000家 企业，携 数万款 前沿产品集中亮相 ，以"创新科技，智领未来"为主题，共同探讨医疗科技的突破与未来。 CMEF不仅是一场产品与技术的集中展示，更是医疗行业生态的一次深度联动。从人工智能驱动的医学影像，到手术机器人赋能精准医疗，从智慧医院建设，到国 产医疗设备的崛起，CMEF2025通过高规格论坛、产业对话和技术展示，构建起全方位的交流平台，为行业发展提供新的思路与动能。 在这一医疗科技的年度盛会上，哪些企业将携最新技术亮相？哪些创新产品值得重点关注？ 思宇梳理了本届CMEF的亮点企业，一起来看它们如何在这场科技盛宴 中抢占先机！ P.S. 展位图附于文末，感兴趣的读者可按图索骥 ...

最新一期业绩显示，2024年三季报，公司实现营业收入13.98亿元，同比-4.74%；净利润1.09亿元，同 比-66.01%，销售毛利率66.59%。 序号股票简称PE(TTM)PE(静)市净率总市值(元)93开立医疗54.1828.954.22131.54亿行业平均 46.4650.224.93109.40亿行业中值33.0731.042.5248.44亿1硕世生物-1956.94-1956.941.2340.43亿2诺唯 赞-583.67-583.672.5299.23亿3博晖创新-305.50-188.093.3746.89亿4康泰医学-294.1934.523.0157.22亿5华 大基因-216.51236.822.24220.01亿6奥精医疗-121.42-121.421.5522.00亿7睿昂基因-83.80-83.801.3012.12亿 8热景生物-57.27-57.273.15102.65亿9华大智造-54.80-54.804.11328.30亿10中红医疗-54.40-37.010.8648.44 亿11天智航-46.58-46.584.8657.34亿 4月1日，开立医疗今日收盘30 ...

一、本次股东股份质押的基本情况 1、本次股份解除质押情况 证券代码：300633 证券简称：开立医疗 公告编号：2025-002 深圳开立生物医疗科技股份有限公司 关于控股股东部分股份解除质押及再质押的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 深圳开立生物医疗科技股份有限公司（以下简称"公司"）近日收到公司 控股股东之一陈志强先生的通知，获悉其将所持有的公司部分股份办理了解除 质押及再质押手续，具体事项如下： 截至本公告披露日，公司控股股东陈志强先生、吴坤祥先生（一致行动 人）所持公司股份累计质押情况如下： | 股东 | 是否为控 股股东及 | 本次解除 质押股份 | 占其所 持股份 | 占公司 总股本 | 起始日 | 解除日期 | 质权人 | | --- | --- | --- | --- | --- | --- | --- | --- | | 名称 | 其一致行 动人 | 数量 | 比例 | 比例 | | | | | 陈志 | | | | | 2023-04- | 2025-03- | 中国银河 | | 强 | 是 | 3,000,000 | ...

Summary of the Conference Call for Kaili Medical Company Overview - Kaili Medical is a leading domestic enterprise in ultrasound and software, initially focused on ultrasound and expanded into soft endoscopy in 2012, becoming the market leader in soft endoscopy. [3][4] - The company has developed a comprehensive product layout from internal medicine to surgery, diagnosis to treatment, and equipment to consumables. [4][5] Key Insights and Arguments - **Market Recovery Expectations**: The bidding recovery in 2025 is expected to be better than in 2024, driven by the release of pent-up demand and improvements in the industry ecosystem. The ultrasound business is anticipated to recover more significantly due to equipment upgrade projects. [4][5] - **New Product Launches**: The new soft endoscope HHD650 has been approved and is expected to enter the market in the second half of the year, enhancing the 4K product line and potentially increasing market share. Additionally, the company has launched the 80 series high-end ultrasound equipment, integrating AI technology for obstetric applications. [4][6] - **Revenue Structure**: The company's revenue primarily comes from ultrasound (50%-60%) and medical software development (approximately 40%), with domestic revenue accounting for about 50% and overseas revenue for about 40%. [7] - **Market Position**: In the domestic ultrasound market, foreign companies hold significant shares, but domestic players like Mindray and Kaili have entered the top five, with Mindray holding a 32% market share in 2023 and Kaili at 7%. [4][8] - **Endoscopy Market Dynamics**: The domestic digestive endoscopy market is mainly dominated by Japanese companies, but domestic companies, including Kaili, are increasing their market share, with Anba holding around 45% and two domestic companies combined nearing 20%. [9] Additional Important Points - **Technological Innovations**: Kaili Medical has made significant technological advancements, such as applying CMOS chips in medical devices to break the long-standing monopoly of CCD sensors by Japanese companies. [10][11] - **AI Integration**: The integration of AI with ultrasound, such as the Fengyan technology for obstetric applications, has been clinically validated and approved, enhancing diagnostic accuracy and competitiveness. [12] - **Future Business Directions**: The company plans to expand into minimally invasive surgery and hardware-related emerging fields, aiming to enhance overall competitiveness and profitability. [13] - **Cardiovascular and Minimally Invasive Surgery Performance**: The company is still in the investment phase for its cardiovascular business, particularly in intravascular ultrasound (IVUS), with expectations of market penetration increasing as domestic alternatives and centralized procurement progress. [14][15] - **Outlook for 2025**: The outlook for Kaili Medical in 2025 is positive, with expectations of improved fundamentals, recovery in terminal bidding demand, and significant growth in ultrasound product sales due to equipment upgrade projects. [16]